butyl-(3-chloro-propyl)-ether | 68032-99-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: butyl-(3-chloro-propyl)-ether
• 英文别名: Butyl-(3-chlor-propyl)-aether；1-Butoxy-3-chlor-propan；1-Chloro-3-butoxypropane；1-(3-chloropropoxy)butane
• CAS: 68032-99-5
• 化学式: C₇H₁₅ClO
• 分子量: 150.649
• InChiKey: PPNRREMIPBRCCD-UHFFFAOYSA-N

物化性质

• 沸点：
  70-80 °C(Press: 22 Torr)
• 密度：
  0.930±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  butyl-(3-chloro-propyl)-ether 、 二乙胺 在 potassium iodide 作用下， 生成 diethyl-(3-butoxy-propyl)-amine
  参考文献：
  名称：

  Yasue, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1953, vol. 73, p. 290

  摘要：

  DOI：
• 作为产物：
  描述：

  3-丁氧基-1-丙醇 在 氯化亚砜 作用下， 生成 butyl-(3-chloro-propyl)-ether
  参考文献：
  名称：

  Yasue, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1953, vol. 73, p. 290

  摘要：

  DOI：

文献信息

• [EN] PROCESS FOR PREPARING BENZOXABOROLES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE BENZOXABOROLES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011127143A1

  公开（公告）日：2011-10-13

  The present invention is a process comprising contacting a compound of formula 6: or a pharmaceutically acceptable salt thereof; with a deprotecting reagent to form a compound of formula A: or a pharmaceutically acceptable salt thereof; where R is H or OR1; R1 and each R1' are protecting groups; R1" is H or OH, and n is 0, 1, 2, 3, 4, or 5.

  本发明涉及一种工艺，包括将式6的化合物或其药学上可接受的盐与去保护试剂接触，以形成式A的化合物或其药学上可接受的盐，其中R为H或OR1；R1和每个R1'为保护基；R1"为H或OH，n为0、1、2、3、4或5。
• 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
  申请人：——

  公开号：US20030105098A1

  公开（公告）日：2003-06-05

  The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.

  本发明涉及6-9-二取代的2- [转-（4-氨基环己基）]氨基嘌呤，其在抑制细胞周期依赖性激酶，特别是cdk-2方面具有用途。本发明还提供了一种预防神经细胞凋亡和抑制肿瘤发展的方法。
• 6, 9-disubstituted 2-&lsqb;trans-(4-aminocyclohexyl)amino&rsqb; purines
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06479487B1

  公开（公告）日：2002-11-12

  The present invention provides novel compounds of the formula (I) wherein R is selected from the group consisting of R2, R2NH—, or R3R4N—R5- wherein R2 is selected from the group consisting of C9-C12 alkyl, Z is selected from the group consisting of phenyl, heterocycle, cycloalkyl, and naphthanlene; and M is selected from the group consisting of hydrogen, C1-C4 alkyl, and wherein each C9-C12 alkyl or Z is optionally substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, and C1-C4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C1-C8 alkyl; R3 and R4 are selected from the group consisting of hydrogen, C1-C4 alkyl and (CH2)y-phenyl, wherein y is an integer 0-8, with the proviso that R3 and R4 not both be hydrogen; R5 is C1-C8 alkylene; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers, and hydrates thereof, with the proviso that when R2 is the group wherein n is 1 or greater; R1 is isopropyl or cyclopentyl; R6 is hydrogen, C1-C4 alkyl, or (CH2)m-phenyl; and Z is phenyl, heterocycle, or cycloalkyl, that Z is substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting of In addition, the present invention provides a method of inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.

  本发明提供了公式(I)的新化合物，其中R选自R2、R2NH-或R3R4N-R5-组成的群，其中R2选自C9-C12烷基，Z选自苯基、杂环、环烷基和萘基；M选自氢、C1-C4烷基和其中每个C9-C12烷基或Z可选择地被1-3个取代基取代，这些取代基可以相同也可以不同，选自D、E组成的群，其中每个D独立地选自三氟甲基、三氟甲氧基和C1-C4烷氧基；每个E独立地选自卤素、羟基和C1-C8烷基；R3和R4选自氢、C1-C4烷基和(CH2)y-苯基，其中y是0-8的整数，但R3和R4不能同时为氢；R5是C1-C8烷基；R1选自环戊基、环戊烯基和异丙基，以及其药学上可接受的盐、光学异构体和水合物，但当R2为n为1或更大的基团时；R1为异丙基或环戊基；R6为氢、C1-C4烷基或(CH2)m-苯基；Z为苯基、杂环或环烷基，但Z被1-3个取代基取代，这些取代基可以相同也可以不同，选自此外，本发明提供了一种抑制细胞周期依赖性激酶，特别是cdk-2的方法。本发明还提供了一种预防神经细胞凋亡和抑制肿瘤发展的方法。
• 6,9-disubstituted 2-&lsqb;trans-(4-aminocyclohexyl)amino&rsqb; purines
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06642231B2

  公开（公告）日：2003-11-04

  The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.

  本发明涉及6-9-二取代的2-[trans-(4-氨基环己基)氨基]嘌呤，其对抑制细胞周期依赖性激酶，特别是cdk-2具有用处。本发明还提供了一种预防神经细胞凋亡和抑制肿瘤发展的方法。
• Sulfamides as Endothelin Receptor Antagonists for the Treatment of Cardiovascular Diseases
  申请人：Bolli Martin

  公开号：US20080004298A1

  公开（公告）日：2008-01-03

  The invention relates to novel sulfamic acid amides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

  本发明涉及新型磺酰胺酸酯及其在制备药物组成物中作为活性成分的用途。本发明还涉及相关方面，包括含有这些化合物中的一个或多个的药物组成物，特别是它们作为内皮素受体拮抗剂的用途。